Journal of Oncology Pharmacy Practice最新文献

{"title":"Advancements and challenges in CAR T cell therapy for pediatric brain tumors: A review.","authors":"Yasmina Gaoual, Adam Mahyaoui, Lamyae Yachi, Mustapha Bouatia, Zineb Aliat, Younes Rahali","doi":"10.1177/10781552251331609","DOIUrl":"10.1177/10781552251331609","url":null,"abstract":"<p><p>Chimeric Antigen Receptor (CAR) T cell therapy represents a groundbreaking advancement in immunotherapy, initially gaining FDA approval for treating hematological malignancies. This therapy has shown promising results in solid tumors, particularly in pediatric brain tumors, which are the leading cause of cancer-related death in children. CAR T cells are engineered to target specific antigens on tumor cells, thereby reducing off-target effects and increasing the cytotoxic impact on cancer cells. Over the years, CAR T cell technology has evolved through five generations, each enhancing the structure, functionality, and safety of these cells. Despite these advancements, the application of CAR T cells in solid tumors, especially within the central nervous system (CNS), faces significant challenges. These include the physical barrier posed by the blood-brain barrier (BBB), the immunosuppressive tumor microenvironment (TME), and the heterogeneity of tumor antigens. The review discusses several promising antigenic targets for CAR T cells in pediatric brain tumors, such as HER2, EphA2, IL-13Rα2, and Survivin, which have been explored in recent clinical trials. These trials have shown early promise in improving patient outcomes, though the risks of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain concerns. The future of CAR T cell therapy lies in overcoming these barriers through innovative approaches like \"Armored CARs\" or TRUCKs, designed to modulate the TME and improve CAR T cell efficacy in solid tumors. Additionally, combination therapies and safety switches in next-generation CAR T cells are being explored to enhance therapeutic potential while minimizing adverse effects.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1150-1158"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using bispecific antibodies in a patient with peritoneal dialysis for relapsed multiple myeloma.","authors":"Heng Jiang, Yagya Ahlawat, Amir Steinberg","doi":"10.1177/10781552251341235","DOIUrl":"10.1177/10781552251341235","url":null,"abstract":"<p><p>IntroductionBispecific antibodies (BsAbs) are a promising therapy for relapsed/refractory multiple myeloma (RRMM), but their efficacy in patients with end-stage renal disease (ESRD) on peritoneal dialysis (PD) remains unclear. Given the prevalence of renal impairment in MM, understanding BsAbs' use in this population is critical.Case ReportWe present a 72-year-old woman with ESRD on PD diagnosed with RRMM after developing a pathologic humeral fracture. Bone marrow biopsy confirmed lambda light chain multiple myeloma with extensive skeletal involvement.Management & OutcomeThe patient was treated with upfront radiation, and then received daratumumab, cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD), followed by carfilzomib, lenalidomide, and dexamethasone (KRd) upon progression. Due to limited response, teclistamab was initiated, achieving a significant but transient response, prompting a switch to talquetamab. Following relapse, she was transitioned to elotuzumab, pomalidomide, and dexamethasone, then selinexor as a bridge to chimeric antigen receptor T-cell (CAR-T) therapy.DiscussionThis case demonstrates that BsAbs may be effective in RRMM patients on PD, though responses were transient. Further research is needed to explore BsAbs' pharmacokinetics, optimal dosing, and long-term outcomes in dialysis-dependent MM patients.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1179-1182"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of chemical contamination by cancer drugs during use of the RIVA^TM compounding robot: A pilot study.","authors":"Myriam Bouchfaa, Michèle Vasseur, Justin Courtin, Marine Pinturaud, Nicolas Beauval, Delphine Allorge, Pascal Odou, Nicolas Simon","doi":"10.1177/10781552241276530","DOIUrl":"10.1177/10781552241276530","url":null,"abstract":"<p><p>IntroductionMany hospitals are now investing in robotic compounding system for the preparation of cytotoxic agents. The objective of the present study was to describe contamination by cytotoxics inside and outside the RIVA^TM robot (ARxIUM, Winnipeg, Canada).Material & MethodsWe applied a risk analysis to determine which locations inside and outside the compounding robot should be monitored. Samples were collected by swabbing with a wet swab (using 0.1 mL of sterile water) before the robots was cleaned. Ten cytotoxics compounded with the robot were screened for using LC-MS/MS. We determined the percentage contamination rates inside (CR_in) and outside (CR_out) the robot and the amounts of each contaminant (in ng/cm²). If a sample was found to be positive, a corrective action was implemented.ResultsOur risk analysis highlighted 10 locations inside the robot and 7 outside. Ten sampling campaigns (10 samples per campaign) were performed. The mean CR_in (40%) was significantly higher than the mean CR_out (2%; p < 10^-4). Gemcitabine and cyclophosphamide were the main contaminants. After the implementation of corrective measures (such as daily cleaning with SDS/isopropyl alcohol), the CR_in fell from 60% to 10%.Discussion/conclusionThe frequency of contamination was lower for robotic compounding than for manual compounding in an isolator. However, robotic compounding tended to generated larger mean amounts of contaminant; this was related to incidents such as splashing when syringes were disposed of after the compounding. The implementation of corrective actions effectively reduced the CRs. Further longer-term studies are required to confirm these results.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1061-1070"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to Audit on Oral Systemic Anti-Cancer Therapies (SACT) Adherence Using the Morisky Medication Adherence Scale (MMAS): Implications for Pharmacy Counselling.","authors":"","doi":"10.1177/10781552251347796","DOIUrl":"10.1177/10781552251347796","url":null,"abstract":"","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1194"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of fluid overload in allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide.","authors":"Megan Tsao, Rasmus Hoeg, Joshua Pecoraro, Megan Kuehner, Brittany Deen, Julie Guglielmo","doi":"10.1177/10781552241276418","DOIUrl":"10.1177/10781552241276418","url":null,"abstract":"<p><p>BackgroundFluid overload (FO) commonly occurs during hospitalization for allogeneic hematopoietic cell transplantation (HCT). Grade 2-4 FO is associated with day +100 non-relapse mortality.1 Post-transplant cyclophosphamide (PTCY) for graft-versus-host disease prevention requires aggressive IV hydration to prevent hemorrhagic cystitis.Materials and MethodsThis is a single-center, retrospective, observational study conducted at an academic medical center via electronic chart review. Included patients received allogeneic HCT followed by PTCY on days +3 and +4. Patients were excluded for age < 18 years or incarceration. Primary endpoints are incidence of Grade 2-4 FO and associated risk factors. Descriptive and inferential statistics (i.e., <b>Fisher's exact test</b>, <b>multivariable regression analysis) were</b> used.ResultsOf 97 patients screened, 95 were included and 2 were excluded due to absence of weight measurements needed to grade FO. Median age was 60 years, 66.3% were male, 91.6% received reduced-intensity conditioning, 72.6% received haploidentical HCT, 44.2% were ECOG 0, and 11.6% had diastolic dysfunction. Incidence of grade 2-4 FO was 33.7% (n = 32). Univariate analyses found age (continuous; p = 0.04) and BSA < 1.7 m² (p = 0.006) as independent factors associated with grade 2-4 FO. Multivariable regression analysis found 3.3% higher risk with every 1-year increase in age ranging from f 20 to 78 years (OR 1.033, 95% CI 1.001, 1.006; p = 0.0453) and 82.8% lower risk with BSA ≥ 1.7 m² (OR 0.172, 95% CI 0.051, 0.588; p = 0.005) after adjusting for co-variates.Conclusion(s)Increasing age and BSA < 1.7 m² are risk factors associated with grade 2-4 FO during hospitalization for allogeneic HCT with PTCY.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1046-1050"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rechallenge of an alternative CDK 4/6 inhibitor after hepatotoxicity in the treatment of hormone-positive metastatic breast cancer.","authors":"Kasey Jackson, Kiera Roubal, Christopher Rangel, Frank Brescia","doi":"10.1177/10781552251340613","DOIUrl":"10.1177/10781552251340613","url":null,"abstract":"<p><p>IntroductionCyclin Dependent Kinase (CDK) 4/6 inhibitors are changing the landscape of breast cancer treatment. These medications are generally well-tolerated, but incidences of hepatotoxicity have been reported in the literature.Case ReportIn this case, we present a 36-year-old Caucasian female who was diagnosed with hormone-receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer who initiated first line treatment with an aromatase inhibitor and a cyclin-dependent kinase (CDK) 4/6 inhibitor, ribociclib. Following treatment initiation, she experienced grade 4 hepatoxicity.Management and OutcomeRibociclib was discontinued due to probable cause of hepatotoxicity based on a Naranjo score of 7. Once her liver enzymes resolved to grade 1 toxicity, she was transitioned to another CDK 4/6 inhibitor, palbociclib. The patient has remained on palbociclib for 1 year of treatment with normalization of her liver function enzymes and stable disease.DiscussionThis case presents a successful rechallenge of an alternative CDK 4/6 inhibitor after grade 4 ribociclib-induced hepatotoxicity and reviews similar cases of ribociclib-induced hepatoxicity and management strategies.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1174-1178"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Pharmacists' Perspectives on the Need for an App to Assess Chemotherapy Drug-Related Problems in Indonesia: A Qualitative Study.","authors":"Ani Anggriani, Eli Halimah, Siti Saidah Mutmainah, Farida Rendrayani, Rano Kurnia Sinuraya, Irma Melyani Puspitasari","doi":"10.1177/10781552251383788","DOIUrl":"https://doi.org/10.1177/10781552251383788","url":null,"abstract":"<p><p>IntroductionClinical pharmacists play a crucial role in identifying drug-related problems (DRPs) during the assessment of chemotherapy regimens. In hospitals, this assessment involves identification, intervention, and resolution. However, since the process is largely conducted manually, it becomes time-consuming and inefficient. This study aims to explore the perspectives of clinical pharmacists regarding the current chemotherapy regimen DRPs assessment process and the need for an application (app) to improve and streamline this assessment.MethodsA focus group discussion (FGD) was conducted with 11 clinical pharmacists responsible for reviewing chemotherapy regimens at a hospital in Indonesia. The discussions were recorded, transcribed, and analyzed using NVivo 15.0.0.ResultsThe current DRPs assessment is time-consuming due to redundant documentation, requiring daily data entry and reentry for monthly reports. Issues include long processing times and potential body surface area (BSA) and dose calculation errors. Clinical pharmacists expressed the need for a DRPs app to streamline workflow and reduce errors. They emphasized clear, readable fonts, a purple color scheme, and a comprehensive drug database aligned with hospital, Ministry of Health, and national formulary standards. The app should be user-friendly and accessible on both computers and smartphones.ConclusionsThis study highlights that the current manual handwriting-based DRPs assessment process for chemotherapy regimens is inefficient and requires repeated documentation. Clinical pharmacists strongly advocate for the development of an app that streamlines the assessment of DRPs, facilitates accurate and timely reporting of medication errors, and enhances overall efficiency in chemotherapy regimen evaluations.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251383788"},"PeriodicalIF":0.9,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reducing drug-related problems in hospitalized pediatric cancer patients through clinical pharmacist interventions: An interventional study from Turkey.","authors":"Ömer Faruk Özkanlı, Ahmet Koç, Nurşah Eker, Mesut Sancar","doi":"10.1177/10781552251383020","DOIUrl":"https://doi.org/10.1177/10781552251383020","url":null,"abstract":"<p><strong>Introduction: </strong>Clinical pharmacists play a vital role in reviewing anticancer regimens, dose calculations, managing drug-related problems, and monitoring adverse drug reactions. The aim of this study was to identify, classify and reduce drug-related problems in patients with neoplastic disease hospitalized in the pediatric hematology-oncology clinic.</p><p><strong>Methods: </strong>The study was a prospective, interventional study consisting of observation and intervention periods conducted for five months, from April 2024 to August 2024. During the intervention period of the study, clinical pharmacist recommendations for drug-related problems were presented to the healthcare team. Drug-related problems was used in Pharmaceutical Care Network Version 9.1 and were classified according to their clinical significance.</p><p><strong>Results: </strong>A total of 80 patients were included in the study. The median (interquartile range) age of all patients was 7.5 years (4-12.75) and 61.3% were boy. The most common malignancies are acute lymphoblastic leukemia (32.5%) and medulloblastoma (10%). A total of 457 drug-related problems were detected in all periods, 147 of the 457 drug-related problems were related to ''not clinically significant'' drug-drug interactions. In the intervention period, the frequency of all drug-related problems decreased by 56.3% (<i>p</i> < 0.001). The most common causes of drug-related problems were drug-drug interactions (47.7%), other causes (13.8%), and indication no treatment (9.1%). During the intervention period, recommendations were made for 66 of the 138 drug-related problems identified, and all of these recommendations (100%) were accepted by physicians. The intervention period recommendations were mostly in the form of drug dose change (35.3%), change in instructions for use (27.4%), drug change (11.77%) and drug paused/stopped (11.77%). 37% of patients who received chemotherapy had adverse events during and after chemotherapy, and during their hospital stay. The most common chemotherapy-related adverse events were leukopenia (20%), lymphopenia (17.5%), and neutropenia (13.8%).</p><p><strong>Conclusions: </strong>A high incidence of drug-related problems was detected in patients with neoplastic disease hospitalized in the pediatric hematology-oncology clinic. All of the clinical pharmacist's recommendations were accepted by the healthcare team.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251383020"},"PeriodicalIF":0.9,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corneal edema and epithelial defect during pralsetinib treatment.","authors":"Neslihan Bayraktar Bilen, Rabia Barış, Döndü Melek Ulusoy","doi":"10.1177/10781552251381795","DOIUrl":"https://doi.org/10.1177/10781552251381795","url":null,"abstract":"<p><p>IntroductionThis article describes an unusual case of corneal edema with epithelial defect associated with pralsetinib, an oral rearranged during transfection (RET) inhibitor and used for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC).Case reportA 64-year-old man with metastatic NSCLC diagnosis had applied to the ophthalmology clinic with the complaint of blurred vision at the second month of pralsetinib therapy. Ocular examination revealed unilateral corneal epithelial defect and corneal edema. To our knowledge, this is the first case report of corneal disease due to pralsetinib usage.Management and outcomeThere was no improvement in the patient's clinical condition with medical treatment. Pralsetinib was stopped in consultation with the Oncology Department. 2 weeks later, the corneal findings improved and visual acuity increased. The patient was much better 1 months later.DiscussionThis case report describes corneal edema with epithelial defect as a rare side effect of pralsetinib and highlights the importance of collaboration between oncologists and ophthalmologists.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251381795"},"PeriodicalIF":0.9,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145192000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility study of an innovative simulation-based learning program in hospital oncology pharmacy: A pilot project in a faculty of pharmacy.","authors":"Oualid Ziraoui, Zineb Lachhab, Youssef Baztami, Anass Babakhouya, Omar El Hamdaoui, Soumaya El Baraka, Said Zouhair","doi":"10.1177/10781552251367346","DOIUrl":"https://doi.org/10.1177/10781552251367346","url":null,"abstract":"<p><p>ObjectiveThis study investigates the feasibility of introducing a pilot program at the Faculty of Medicine and Pharmacy in Marrakech to incorporate simulation-based learning (SBL) specifically in the field of oncology pharmacy. The aim is to modernize pharmacy education and enhance the training of future oncology pharmacists, ultimately improving the quality of cancer care in Moroccan hospitals.MethodA cross-sectional questionnaire was conducted during the 2024-2025 academic year, including 189 pharmacy students. A structured questionnaire assessed their perceptions, attitudes, and the alignment of SBL with key competencies in oncology pharmacy practice. The study compared traditional teaching methods (TTM) with SBL, highlighting techniques such as role-playing, standardized patients, and computer-assisted simulations focused on oncology-specific scenarios, including chemotherapy preparation and patient counseling.ResultsMost participants (86.6%) agreed that SBL significantly improved memory retention and learning, while 73% noted that it reduced the time required to acquire oncology-specific skills. Furthermore, 84.7% found SBL highly relevant to oncology pharmacy practice. The majority of students expressed interest in SBL programs, primarily for their practical relevance (68.3%) and interactive nature (63.5%). In terms of implementation, 66.7% of participants reported they would seek help from instructors if challenges arose, while 65.6% would turn to peers.Discussion and ConclusionSBL emerges as a powerful tool to bridge the gap between theoretical knowledge and clinical practice in oncology pharmacy. By integrating advanced technologies, such as artificial intelligence, and fostering interdisciplinary collaboration, pharmacy education can better prepare students for the complexities of cancer care in hospital settings.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251367346"},"PeriodicalIF":0.9,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145176139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}